• Publications
  • Influence
Asset stock accumulation and sustainability of competitive advantage
Given incomplete factor markets, appropriate time paths of flow variables must be chosen to build required stocks of assets. That is, critical resources are accumulated rather than acquired inExpand
  • 7,790
  • 389
  • PDF
Asset Stock Accumulation and the Sustainability of Competitive Advantage: Reply
Authors' reply to comments regarding their paper Dierickx, I., K. Cool. 1989. Asset stock accumulation and the sustainability of competitive advantage. Management Sci..
  • 585
  • 28
Rivalry, Strategic Groups and Firm Profitability
An analysis of the U.S. pharmaceutical industry during the period 1963–82 finds that a substantial decline in industry profitability is not explained by changes in the number and size distribution ofExpand
  • 279
  • 10
Indirect taxation and cournot equilibrium
We analyse a Cournot model of oligopoly in an industry which is subject to indirect taxation. We consider value added as well as excise taxes. We allow for various types of demand and costExpand
  • 41
  • 7
Business strategy, market structure and risk-return relationships: a structural approach
A structural model is proposed which integrates and extends previous findings on the interrelations between risk—return outcomes, market share, firm conduct attributes, and inter-firm rivalry. It isExpand
  • 209
  • 4
Cost differences and survival in declining industries: A case for ‘picking winners’?
Abstract In this paper, we examine the relationship between firms' cost structures and the order of exit from declining industries. We distinguish between two fundamental causes of demand decline,Expand
  • 15
  • 2
Information asymmetries how not to ‘buy a lemon’ in negotiating mergers and acquisitions
Companies involved in merger and acquisition deals are up against a fundamental problem when they negotiate. Information is asymmetrical, i.e. unequally divided between buyer and seller. There areExpand
  • 21
  • 1
RIVALRY, STRATEGIC GROUPS AND FIRM
An analysis of the U.S. pharmaceutical industry during the period 1963-82 finds that a substantial decline in industry profitability is not explained by changes in the number and size distribution ofExpand
  • 9